Empire Life Investments’s Stemline Therapeutics, Inc. STML Stock Holding History

Empire Life Investments’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-941,249	Closed	-$4.56M	–	110
2020 Q1	$4.56M	Buy	941,249 +369,026	+64%	+$2.39M	0.42%	54
2019 Q4	$6.08M	Buy	572,223 +57,954	+11%	+$575K	0.46%	50
2019 Q3	$5.35M	Buy	514,269 +177,645	+53%	+$2.32M	0.45%	53
2019 Q2	$5.16M	Sell	336,624 -36,562	-10%	-$529K	0.42%	65
2019 Q1	$4.79M	Sell	373,186 -677	-0.2%	-$7.65K	0.4%	66
2018 Q4	$3.55M	Buy	373,863 +274,742	+277%	+$3.56M	0.32%	68
2018 Q3	$1.65M	Buy	99,121 +65,357	+194%	+$1.05M	0.13%	81
2018 Q2	$542K	Buy	33,764 +151	+0.4%	+$2.69K	0.04%	87
2018 Q1	$514K	Hold	33,613	–	–	0.04%	91
2017 Q4	$524K	Hold	33,613	–	–	0.04%	85
2017 Q3	$373K	Buy	+33,613	New	+$316K	0.03%	98

Empire Life Investments's STML Position: Q2 2020 in Review

Empire Life Investments sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 941,249 shares — an estimated $4.56M sold.

Empire Life Investments first reported a position in STML in Q3 2017 and held it in 11 quarters. The position peaked at $6.08M in Q4 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

Empire Life Investments reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
Empire Life Investments sold 941,249 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $4.56M.
Empire Life Investments first reported a position in Stemline Therapeutics, Inc. in Q3 2017 and held it in 11 quarters.
Empire Life Investments's Stemline Therapeutics, Inc. position peaked at $6.08M in Q4 2019.
0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Empire Life Investments's 13F filing for Q2 2020, filed 3 Aug 2020.